WASHINGTON, D.C.—A 70-year-old woman had been diagnosed with rotator cuff disease three years earlier and received an array of treatments. What she hadn’t received was an X-ray. She’d had an MRI, and her doctor—not an orthopedist or a rheumatologist, but a primary care physician—had zeroed in on degenerative changes in her rotator cuff. The problem,…
Psoriatic Arthritis Linked to Increased Heart Disease Risk
(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…
Pulse Therapy & Lupus Nephritis: A 40-Year History, 1976–2016
Corticosteroids still represent the mainstay of treatment of patients with active disease. They have been used for more than 60 years, and although prolonged use is associated with organ damage, they have been shown to be lifesaving in various phases of the history of the disease. History of Use First introduced in the late 1960s…
Do Fevers Offer Insight into Diagnosis & Disease?
Patients experience fevers for many reasons, but can they help physicians diagnose disease? Using modern technology and social media, Jonathan S. Hausmann, MD, is working to further the understanding of body temperatures…
Benefits of Secukinumab in Ankylosing Spondylitis May Persist at 2 Years
NEW YORK (Reuters Health)—Secukinumab appears to improve clinical and radiographic outcomes of ankylosing spondylitis (AS) through two years of therapy, according to new results from the MEASURE 1 study. Secukinumab is a fully human monoclonal antibody against interleukin-17A, which is implicated in various pathophysiological features of spondyloarthritis. In a report online Dec. 13 in the…
Research Identifies Two New Cell Types in Sjögren’s Syndrome
Two previously unidentified cellular players in the pathogenesis of primary Sjogren’s syndrome (pSS) have been discovered: a regulatory T cell (Prdm1+eTreg) and a helper T cell (Il21+Th1). In the study, researchers also identified the transcriptional signatures of these cells and their differential dependency on the lymphotoxin/LIGHT signaling axis, which may guide future therapeutic interventions…
FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling
The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…
Does Telephone Coaching Enhance Physical Activity Programs?
Health coaching by telephone is increasingly being used to assist in chronic disease self-management. A recent study examined the benefits of simultaneous health coaching via telephone as an addition to a physiotherapist-prescribed home-based physical activity program for patients with knee OA. Although participants receiving additional coaching had a short-term improvement in adherence, changes in pain and function did not differ between the study’s groups at six months…
Liquid Biopsy Provides Insights into Lupus
Microparticles in the blood of SLE patients may be a source of extracellular HMGB1, which is involved in immune response. Researchers found that analysis may be able to determine if the patient is producing dead, dying and activated cells that are important for SLE pathogenesis…
Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…
- « Previous Page
- 1
- …
- 193
- 194
- 195
- 196
- 197
- …
- 331
- Next Page »